• About us
• Contact

Advertisement

Organisation › Details

Oculis S.A.

Oculis is a global biopharmaceutical company (NASDAQ: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors. Oculis’ shares and warrants will trade on the Nasdaq Stock Market under the ticker symbols “OCS” and “OCSAW”, respectively. *

 

	Start	2019-01-04 existent
	Group	Oculis (Group)
	Industry	solubilizing nanoparticle (SNP) drug delivery platform (Oculis)
	Industry 2	OC-118 (Oculis)
	Person	Sherif, Riad (Oculis 201801– CEO before Novartis Area President EMEA at Alcon)
	Person 2	Jóhannesson, Páll Ragnar (Oculis 201801– CFO Oculis SA + Managing Director Oculis ehf before CEO Oculis)
	Street	EPFL Innovation Park, Building C EPFL Innovation Park, Building C
	City	1015 Lausanne VD
	Tel	+41-21-711-3970
		Address record changed: 2023-03-09
Basic data	Employees	n. a.
		* Document for »About Section«: Oculis Holding AG. (3/3/23). "Press Release: Oculis Announces US Public Listing on NASDAQ". Lausanne & Zug.
		Record changed: 2023-07-10

Advertisement

More documents for Oculis (Group)

• [1] Oculis Holding AG. (3/3/23). "Press Release: Oculis Announces US Public Listing on NASDAQ". Lausanne & Zug....
• [2] Oculis S.A.. (5/4/21). "Press Release: Oculis Announces an Oversubscribed US$57 million Series C Financing". Lausanne....
• [3] Life Sciences Partners (LSP). (3/18/21). "Press Release: LSP Announces Closing of Upsized $120 Million Nasdaq IPO of European Biotech Acquisition Corp (EBAC) Targeting European Biotech". Amsterdam....
• [4] Oculis S.A.. (9/1/20). "Press Release: Oculis Establishes Presence in U.S. and Appoints Sylvia Cheung as Chief Financial Officer". Lausanne....
• [5] Oculis S.A.. (1/4/19). "Press Release: Oculis Raises CHF15.5 Million in an Extension of Its Series B Financing Round – Total Raised CHF35.5 Million". Lausanne....
• [6] Oculis S.A.. (1/4/19). "Press Release: Oculis Expands Portfolio with the In-Licensing of a Novel Phase II-stage Anti-TNF alpha Antibody Fragment". Lausanne....
• [7] Oculis S.A.. (1/4/18). "Press Release: Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases". Lausanne....
• [8] Oculis ehf.. (6/27/17). "Press Release: Eye-drop for Diabetic Retinopathy – Successful Eurostars grant Application". Reykjavik....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.